Caraang Chris, Lanier Gregg M, Gass Alan, Aronow Wilbert S, Gupta Chhaya Aggarwal
Division of Heart Failure and Heart Transplantation, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USA.
Division of Heart Failure and Heart Transplantation, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USA.
Heart Fail Clin. 2017 Jul;13(3):619-632. doi: 10.1016/j.hfc.2017.02.013.
Left ventricular assist devices (LVADs) are an effective therapy for a growing and aging population in the background of limited donor supply. Selecting the proper patient involves assessment of indications, risk factors, scores for overall outcomes, assessment for right ventricular failure, and optimal timing of implantation. LVAD complications have a 5% to 10% perioperative mortality and complications of bleeding, thrombosis, stroke, infection, right ventricular failure, and device failure. As LVAD engineering technology evolves, so will the risk-prediction scores. Hence, more large-scale prospective data from multicenters will continually be required to aid in patient selection, reduce complications, and improve long-term outcomes.
在供体供应有限的背景下，左心室辅助装置（LVADs）对于不断增长的老龄人口是一种有效的治疗方法。选择合适的患者需要评估适应症、风险因素、总体预后评分、右心室衰竭评估以及最佳植入时机。LVAD并发症的围手术期死亡率为5%至10%，还会出现出血、血栓形成、中风、感染、右心室衰竭和装置故障等并发症。随着LVAD工程技术的发展，风险预测评分也会随之变化。因此，将持续需要来自多中心的更多大规模前瞻性数据，以协助患者选择、减少并发症并改善长期预后。
